Tiziana Life Sciences Advances Alzheimer’s Treatment with Intranasal Foralumab

Tiziana Life Sciences ( (TLSA) ) has shared an update.

Tiziana Life Sciences announced the successful dosing of the first patient with moderate Alzheimer’s disease using its lead candidate, intranasal foralumab, marking a significant milestone in its clinical development program. This new treatment approach aims to reduce brain inflammation by stimulating T regulatory cells, offering an alternative to traditional Alzheimer’s therapies. The study, conducted at Brigham and Women’s Hospital, is part of a broader development program supported by a $4 million NIH grant, emphasizing Tiziana’s commitment to addressing unmet medical needs in Alzheimer’s and other inflammatory diseases.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, specifically through alternative routes of immunotherapy. The company’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody, currently the only one in clinical development. Tiziana’s approach potentially offers improved efficacy, safety, and tolerability compared to traditional intravenous delivery methods, with several patents pending to support their pipeline.

YTD Price Performance: 65.89%

Average Trading Volume: 274,065

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $102.8M

For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.